Xeloda
08 »
Xeloda
CapecitabineSystematic (IUPAC) namepentylaminomethanoateIdentifiersCAS number154361-50-9ATC codeL01BC06PubChem60953DrugBankAPRD00203Chemical dataFormulaC15H22FN3O6 Mol. mass359.35 g/molPharmacokinetic dataBioavailabilityExtensiveProtein binding< 60%MetabolismHepatic, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracilHalf life38–45 minutesExcretionRenal 95.5%, faecal 2.6%Therapeutic considerationsPregnancy cat.D(AU) D(US)Legal statusPrescription Only (S4)(AU) POM(UK) ℞-only(US)RoutesOralCapecitabine (INN) (pronounced /keɪpˈsaɪtəbiːn/) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil. Capecitabine is marketed under the trade name Xeloda (Roche).// IndicationsCapecitabine is FDA-approved for:Adjuvant in colorectal cancer Stage III Dukes' C - used as first-line monotherapy.Metastatic colorectal cancer - used as first-line monotherapy, if appropriate.Metastatic breast cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. Also as monotherapy, if the patient has failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons (i.e., the patient has already received the maximum lifetime dose of an anthracycline).In the UK, capecitabine is approved by the National Institute for Health and Clinical Excellence (NICE) for colon and colorectal cancer, and locally advanced or metastatic breast cancer. DoseThe usual starting dose is 2,500 mg/m2/day in two divided doses, 12 hours apart. One cycle includes two weeks of treatment followed by one week without treatment. Cycles can be repeated every three weeks. Dose adjustmentsFor mild renal dysfunction (creatinine clearance 30-50 mL/min), it is recommended to reduce dose by 25%.For severe renal dysfunction (creatinine clearance <30 mL/min), treatment is not recommended.There is no recommendation for hepatic dysfunction.For elderly patients, lower doses may be required due to higher incidences of serious adverse reactions. Side effectsPotential major adverse reactions include:Cardiovascular: EKG changes, myocardial infarction, angina (these may be more common in patients with pre-existing coronary artery disease)Dermatological: Hand-foot syndrome (numbness, tingling, pain, redness, or blistering of the palms of the hands and soles of the feet)Gastrointestinal: Diarrhea (sometimes severe), nausea, stomatitisHematological: Neutropenia, anemia, thrombocytopeniaHepatic: Hyperbilirubinemia Drug interactionsMay interact with warfarin and increase bleeding risk.May inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin and other substrates of CYP2C9.Much as fluorouracil, the concomitant use of leucovorin may increase both the efficacy and the toxicity of capecitabine. FormulationCapecitabine (as brand-name Xeloda) is available in light peach 150 mg tablets and peach 500 mg tablets.
A reader wants to know if Xeloda can also cause strokes.NCCN adding Xeloda to treat advanced Esophogeal and Gstric Cancer. Xeloda is used for treating women with breast cancer that is resistant to other more commonly-used drugs.. It also is used following surgery for colorectal cancer if the cancer has spread to lymph nodes (Dukes' C stage)..Xeloda is a drug used to treat different types of cancers.GlaxoSmithKline is seeking FDA approval to market Tykerb in combination with Xeloda for the treatment of advanced breast cancer in women who have received prior therapy, including Herceptin.finally after favorable results
Even more about Xeloda
Xeloda
XELODA.com provides information and resources for patients, caregivers and healthcare professionals on breast cancer, colorectal cancer and XELODA, the first FDA-approved oral ...
XELODA: The first FDA-approved oral chemotherapy for both advanced ...
Find answers to common patient questions about XELODA and the treatment of breast and colorectal cancer.
XELODA® (capecitabine) Frequently Asked Questions
Xeloda Capecitabine. Xeloda, a unique component of evolving cancer treatment. XELODA plus docetaxel delivers more rapid response and superior survival
XELODA InfoSite
Consumer Information Page ... Xeloda: Brand Name: Xeloda: Active Ingredient: capecitabine
Capecitabine (Xeloda)
Drug information and side-effects for Xeloda ... Useful Websites. specialistinfo.com details of 26,000 UK specialists Global RPH
Comment:
